Therefore, in our experimental settings we evaluated TGF-β serum levels as an index of liver disease progression, also to circumvent the limitation the local ethics committee that allowed us to perform liver biopsy only on a limited group of patients with clinical signs of impaired liver function at the enrolment in the trial. The gene discussed is TGFB1; the disease is liver disorder.